Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) injection 8mg for priority review.

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

Leveraging Trump’s impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US ...